Abstract
Controlled-release salbutamol tablets (Volmax - Ventolin CR) have superseded the now obsolete Ventolin Spandets. This new preparation, marketed as two brands by subsidiaries of Glaxo in pseudo-competition, is a sustained-release formulation designed to provide smooth release of salbutamol over 12 hours allowing twice daily dosage. The manufacturers list as indications “all forms of reversible airflow limitation”, but most would regard inhaled β2agonists and corticosteroids as the best treatment for these conditions. Given the efficacy and safety of these inhaled drugs it is questionable what the aim of oral treatment would be. What then, is the role of controlled-release salbutamol tablets?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
